Shanghai InnoStar Bio-tech Co Ltd celebrated its listing on the Shanghai Stock Exchange’s STAR Market on Sept 3. Trading under the stock code 688710, InnoStar marks a significant milestone as the first publicly listed Contract Research Organization (CRO) subsidiary of a central State-owned enterprise (SOE).

Representatives ring a gong in celebration of InnoStar’s listing on the Shanghai Stock Exchange’s STAR Market on Sept 3, 2024. [Photo/sinopharm.com]

The ceremony was attended by government officials, Sinopharm leadership, representatives of intermediary agencies, shareholders, clients, partners and InnoStar leadership and employees.

Founded in 2010, InnoStar is a majority-owned subsidiary of China State Institute of Pharmaceutical Industry Co Ltd under Sinopharm. The company adheres to the core values of "science orientated, quality first, integrity & dedication, win-win cooperation", strives for innovative development, provides trustworthy services and boosts efficiency through effective management.

InnoStar has achieved numerous industry certifications, including the GLP certification from China’s National Medical Products Administration and the Dutch government, the AAALAC accreditation and the CAP certification from the College of American Pathologists. It also passed GLP inspections by the US Food and Drug Administration.

As a CRO company offering a full suite of non-clinical research services primarily focused on biopharmaceuticals, InnoStar’s business encompasses early-stage druggability assessments, non-clinical pharmacodynamics, non-clinical pharmacokinetics, non-clinical safety evaluations, clinical bio-sample analysis, biomarker studies and translational research.

Looking forward, the company will remain steadfast in its mission of specializing in R&D services and empowering the healthcare industry. InnoStar aims to drive reform and innovation, enhance its core strength and establish itself as a world-class comprehensive CRO enterprise with global competitiveness.